tebentafusp 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
fusion proteins 5513 1874157-95-5

Description:

MoleculeDescription

Molfile

Synonyms:

  • tebentafusp
  • tebentafusp-tebn
  • kimmtrak
  • IMCgp100
  • IMCgp 100
  • ImmTAC IMCgpgp 100
Tebentafusp-tebn is a bispecific gp100 peptide-HLA-A02:01 directed T cell receptor CD3 T cell engager. The TCR arm binds to a gp100 peptide presented by human leukocyte antigen-A*02:01 (HLA¬ A02:01) on the cell surface of uveal melanoma tumor cells. In vitro, tebentafusp-tebn bound to HLA-A02:01-positive uveal melanoma cells and activated polyclonal T cells to release inflammatory cytokines and cytolytic proteins, which results in direct lysis of uveal melanoma tumor cells.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Jan. 25, 2022 FDA IMMUNOCORE LTD
April 1, 2022 EMA IMMUNOCORE IRELAND LIMITED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 145.67 69.16 27 133 27946 90600341

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 95.68 65.84 24 146 44503 42576662

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cytokine release syndrome 185.35 64.17 40 206 70266 110518787

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XX75 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Other antineoplastic agents
MeSH PA D000970 Antineoplastic Agents
FDA MoA N0000175617 CD3-directed Antibody Interactions
FDA MoA N0000175618 CD3 Receptor Agonists
FDA EPC N0000193989 Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager
FDA MoA N0000193994 Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01XX Other antineoplastic agents 33 drugs
adagrasibafliberceptaltretamineamsacrineanagrelidearsenic trioxideasparaginasebelzutifancalaspargase pegolcelecoxibdarinaparsindenileukin diftitox show all 33 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Unresectable uveal melanoma indication
Metastatic uveal melanoma indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
T-cell surface glycoprotein CD3 Surface antigen BINDING AGENT Kd 7.42 DRUG LABEL DRUG LABEL
gp100 peptide‐HLA‐A*02:01 complex Surface antigen BINDING AGENT Kd 10.62 DRUG LABEL DRUG LABEL

External reference:

IDSource
CHEBI:757417 CHEBI
CHEMBL4297990 ChEMBL_ID
C000719808 MESH_SUPPLEMENTAL_RECORD_UI
7378 IUPHAR_LIGAND_ID
DB15283 DRUGBANK_ID
1025311000122109 SNOMEDCT_US
4041128 VANDF
4041129 VANDF
C5139666 UMLSCUI
CHEMBL2109434 ChEMBL_ID
D12296 KEGG_DRUG
10664 INN_ID
355621 MMSL
40399 MMSL
d09847 MMSL
018939 NDDF
N658GY6L3E UNII
2590743 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
KIMMTRAK HUMAN PRESCRIPTION DRUG LABEL 1 80446-401 INJECTION, SOLUTION, CONCENTRATE 100 ug INTRAVENOUS BLA 27 sections